文献速递中毒与环境急症心脑血管急症重症综合管理与镇静镇痛

血清S100B能否预测合成大麻素使用相关的神经元损伤和不良临床结局?S100B在急诊科预测合成大麻素神经元损伤

Could serum S100B be a predictor of neuronal damage and clinical poor outcomes associated with the use of synthetic cannabinoids? S100B to predict neuronal damage of SC in the ED.
PubMed 文献 · Am J Emerg Med · 2017-09-01
一句话结论合成大麻素使用者血清S100B升高,以20 pg/mL为界值时敏感性89.9%、特异性52.0%,有助于风险分层或排除神经元损伤。

本研究纳入30例合成大麻素使用者和30例健康对照,比较血清S100B水平,并以需要气管插管、癫痫发作、需要ICU入住和院内死亡为复合结局。合成大麻素使用者平均S100B为19.3 pg/mL(95%CI 17.7至21.4),对照组为15.9 pg/mL(95%CI 15至16.9)。有复合结局者平均S100B为24.5 pg/mL(95%CI 21.2至27.9),无复合结局者为17.4 pg/mL(95%CI 15.8至18.4)。以20 pg/mL为界值时,敏感性89.9%、特异性52.0%、PPV 44.4%、NPV 91.9%,比值比13.2(95%CI 2.1至28.1)。作者认为S100B可帮助临床医生进行风险分层或可能有助于排除神经元损伤。

要点

  • 合成大麻素使用者平均S100B为19.3 pg/mL(95%CI 17.7至21.4),健康对照为15.9 pg/mL(95%CI 15至16.9),使用者升高。
  • 有复合结局(气管插管、癫痫发作、ICU入住、院内死亡)者平均S100B为24.5 pg/mL(95%CI 21.2至27.9),无复合结局者为17.4 pg/mL(95%CI 15.8至18.4)。
  • 以20 pg/mL为界值时,S100B预测复合结局的敏感性89.9%、特异性52.0%、PPV 44.4%、NPV 91.9%,比值比13.2(95%CI 2.1至28.1)。
  • 作者认为S100B可帮助临床医生进行风险分层,或可能有助于排除神经元损伤。

适用人群与场景

  • 合成大麻素使用者(30例)与健康对照(30例),研究在急诊科进行。

诊断标准与关键阈值

  • 以血清S100B 20 pg/mL为界值(基于最高敏感性设定)预测复合结局。
  • 复合结局定义为需要气管插管、癫痫发作、需要ICU入住和院内死亡。

研究设计与关键结果

  • 研究比较30例合成大麻素使用者与30例健康对照的血清S100B水平,并分析其与复合临床结局的关系。
  • 合成大麻素使用者平均S100B为19.3 pg/mL(95%CI 17.7至21.4),健康对照为15.9 pg/mL(95%CI 15至16.9),平均差-3.6(95%CI -5.6至-1.6)。
  • 有复合结局者平均S100B为24.5 pg/mL(95%CI 21.2至27.9),无复合结局者为17.4 pg/mL(95%CI 15.8至18.4),平均差-7.4(95%CI -10.2至-4.6)。
  • 以20 pg/mL为界值,S100B预测复合结局的敏感性89.9%、特异性52.0%、PPV 44.4%、NPV 91.9%,比值比13.2(95%CI 2.1至28.1)。

证据类型、等级与局限

  • 证据类型:病例对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为血清S100B水平在合成大麻素使用者中升高,可帮助临床医生进行风险分层,或可能有助于排除神经元损伤。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: This study aims to evaluate the serum S100B levels to predict neuronal damage and poor clinical outcomes associated with the use of synthetic cannabinoids.

METHOD: Thirty patients identified as synthetic cannabinoid users and 30 healthy controls were included in the study. S100B levels were compared between healthy controls and synthetic cannabinoid users. The following were considered to be composite outcomes: the need for endotracheal intubation, incidence of seizures, the need for intensive care unit admission, and in-hospital mortality. Clinical and laboratory findings associated with composite clinical outcomes were examined.

RESULTS: The mean S100B level was 19.3 (95% CI: 17.7 to 21.4) pg/mL in patients who use synthetic cannabinoid, and 15.9 (95% CI: 15 to 16.9) pg/mL in the controls; mean df: -3.6 (95% CI: -5.6 to -1.6). In patients with and without composite clinical outcomes, the mean S100B level measured 24.5 (95% CI: 21.2 to 27.9) pg/mL and 17.4 (95% CI: 15.8 to 18.4) pg/mL, respectively; mean df: -7.4 (95% CI: -10.2 to -4.6). With the cut-off value for S100B set at 20pg/mL based on the highest sensitivity, the sensitivity, specificity, PPV, and NPV for S100B were 89.9%, 52.0%, 44.4%, and 91.9%, respectively; odds ratio: 13.2, 95% CI (2.1 to 28.1).

CONCLUSION: Our data suggest that serum S100B levels are elevated in patients using synthetic cannabinoids. These results show that S100B can help clinicians stratify risk or may have a role in excluding those with neuronal damage.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Yilmaz S, Karakayali O, Kale E, et al. Could serum S100B be a predictor of neuronal damage and clinical poor outcomes associated with the use of synthetic cannabinoids? S100B to predict neuronal damage of SC in the ED. Am J Emerg Med. 2017. PMID: 28867154. doi:10.1016/j.ajem.2017.08.053

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。